CLOs on the Move

Millendo

www.millendo.com

 
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing`s Syndrome (CS).
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.millendo.com
  • 301 N. Main Street Suite 100
    Ann Arbor, MI USA 48104
  • Phone: 734.845.9000

Executives

Name Title Contact Details
Jeffery Brinza
 Chief Administrative Officer and General Counsel Profile
Tamara Joseph
 General Counsel and Corporate Secretary Profile

Similar Companies

OncoImmune

Based in Rockville, Maryland, OncoImmune is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biopharmaceuticals for the treatment of cancer and autoimmune disease.

13Therapeutics Inc

13Therapeutics Inc is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fraunhofer Center for Laser Technology

Fraunhofer Center for Laser Technology is a Plymouth, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Translational Genomics Research Institute

The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases.

StemoniX

StemoniX microHeart® products in high density plate formats provide researchers with structurally aligned cardiac cells resembling native human heart tissue with accelerated features of cell maturity.